These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 21836482)

  • 1. Does neoadjuvant therapy alter KRAS and/or MSI results in rectal adenocarcinoma testing?
    Ondrejka SL; Schaeffer DF; Jakubowski MA; Owen DA; Bronner MP
    Am J Surg Pathol; 2011 Sep; 35(9):1327-30. PubMed ID: 21836482
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutations in specific codons of the KRAS oncogene are associated with variable resistance to neoadjuvant chemoradiation therapy in patients with rectal adenocarcinoma.
    Duldulao MP; Lee W; Nelson RA; Li W; Chen Z; Kim J; Garcia-Aguilar J
    Ann Surg Oncol; 2013 Jul; 20(7):2166-71. PubMed ID: 23456389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HER2 status in patients with residual rectal cancer after preoperative chemoradiotherapy: the relationship with molecular results and clinicopathologic features.
    Park JS; Yoon G; Kim HJ; Park SY; Choi GS; Kang MK; Kim JG; Jang JS; Seo AN
    Virchows Arch; 2018 Oct; 473(4):413-423. PubMed ID: 30056472
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical significance of fibroblast growth factor receptor 2 expression in patients with residual rectal cancer after preoperative chemoradiotherapy: relationship with KRAS or BRAF mutations and MSI status.
    Yoon G; Lee H; Kim JH; Hur K; Seo AN
    Tumour Biol; 2016 Aug; 37(8):10209-18. PubMed ID: 26831663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The prognostic role of microsatellite instability, codon-specific KRAS, and BRAF mutations in colon cancer.
    Lin CC; Lin JK; Lin TC; Chen WS; Yang SH; Wang HS; Lan YT; Jiang JK; Yang MH; Chang SC
    J Surg Oncol; 2014 Sep; 110(4):451-7. PubMed ID: 24964758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A prospective pilot study of target-guided personalized chemotherapy with intensity-modulated radiotherapy in patients with early rectal cancer.
    Cubillo A; Hernando-Requejo O; García-García E; Rodriguez-Pascual J; De Vicente E; Morelli P; Rubio C; López-Ríos F; Muro A; López U; Prados S; Quijano Y; Hidalgo M
    Am J Clin Oncol; 2014 Apr; 37(2):117-21. PubMed ID: 23211222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of a biomarker profile associated with resistance to neoadjuvant chemoradiation therapy in rectal cancer.
    Garcia-Aguilar J; Chen Z; Smith DD; Li W; Madoff RD; Cataldo P; Marcet J; Pastor C
    Ann Surg; 2011 Sep; 254(3):486-92; discussion 492-3. PubMed ID: 21865946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of microsatellite instability in sporadic locally advanced rectal cancer following neoadjuvant radiotherapy.
    Du C; Zhao J; Xue W; Dou F; Gu J
    Histopathology; 2013 Apr; 62(5):723-30. PubMed ID: 23425253
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of KRAS mutation as predictor of pathologic response after neoadjuvant chemoradiation therapy for rectal cancer.
    Martellucci J; Alemanno G; Castiglione F; Bergamini C; Valeri A
    Updates Surg; 2015 Mar; 67(1):47-53. PubMed ID: 25702261
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant chemoradiotherapy with or without panitumumab in patients with wild-type KRAS, locally advanced rectal cancer (LARC): a randomized, multicenter, phase II trial SAKK 41/07.
    Helbling D; Bodoky G; Gautschi O; Sun H; Bosman F; Gloor B; Burkhard R; Winterhalder R; Madlung A; Rauch D; Saletti P; Widmer L; Borner M; Baertschi D; Yan P; Benhattar J; Leibundgut EO; Bougel S; Koeberle D
    Ann Oncol; 2013 Mar; 24(3):718-25. PubMed ID: 23139259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. KRAS genotyping in rectal adenocarcinoma specimens with low tumor cellularity after neoadjuvant treatment.
    Boissière-Michot F; Lopez-Crapez E; Frugier H; Berthe ML; Ho-Pun-Cheung A; Assenat E; Maudelonde T; Lamy PJ; Bibeau F
    Mod Pathol; 2012 May; 25(5):731-9. PubMed ID: 22282307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The utility of diagnostic biopsy specimens for predictive molecular testing in colorectal cancer.
    Fadhil W; Ibrahem S; Seth R; AbuAli G; Ragunath K; Kaye P; Ilyas M
    Histopathology; 2012 Dec; 61(6):1117-24. PubMed ID: 22882224
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of alterations in KRAS isoforms KRAS-4A/4B and KRAS mutations in colorectal carcinoma.
    Abubaker J; Bavi P; Al-Haqawi W; Sultana M; Al-Harbi S; Al-Sanea N; Abduljabbar A; Ashari LH; Alhomoud S; Al-Dayel F; Uddin S; Al-Kuraya KS
    J Pathol; 2009 Dec; 219(4):435-45. PubMed ID: 19824059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Poor prognosis of KRAS or BRAF mutant colorectal liver metastasis without microsatellite instability.
    Umeda Y; Nagasaka T; Mori Y; Sadamori H; Sun DS; Shinoura S; Yoshida R; Satoh D; Nobuoka D; Utsumi M; Yoshida K; Yagi T; Fujiwara T
    J Hepatobiliary Pancreat Sci; 2013 Feb; 20(2):223-33. PubMed ID: 23010994
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exclusive KRAS mutation in microsatellite-unstable human colorectal carcinomas with sequence alterations in the DNA mismatch repair gene, MLH1.
    Zhao Y; Miyashita K; Ando T; Kakeji Y; Yamanaka T; Taguchi K; Ushijima T; Oda S; Maehara Y
    Gene; 2008 Nov; 423(2):188-93. PubMed ID: 18692554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preoperative chemoradiation with cetuximab, irinotecan, and capecitabine in patients with locally advanced resectable rectal cancer: a multicenter Phase II study.
    Kim SY; Hong YS; Kim DY; Kim TW; Kim JH; Im SA; Lee KS; Yun T; Jeong SY; Choi HS; Lim SB; Chang HJ; Jung KH
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):677-83. PubMed ID: 20888703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. KRAS and Combined KRAS/TP53 Mutations in Locally Advanced Rectal Cancer are Independently Associated with Decreased Response to Neoadjuvant Therapy.
    Chow OS; Kuk D; Keskin M; Smith JJ; Camacho N; Pelossof R; Chen CT; Chen Z; Avila K; Weiser MR; Berger MF; Patil S; Bergsland E; Garcia-Aguilar J
    Ann Surg Oncol; 2016 Aug; 23(8):2548-55. PubMed ID: 27020587
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Histologic response after neoadjuvant therapy in rectal adenocarcinoma: own experience and review of the literature].
    Mátrai Z; Lövey J; Hitre E; Orosz Z; Gödény M; Péley G; Sulyok Z; Rényi Vámos F; Farkas E; Köves I
    Orv Hetil; 2006 Oct; 147(42):2011-20. PubMed ID: 17165600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Colorectal serrated adenocarcinoma shows a different profile of oncogene mutations, MSI status and DNA repair protein expression compared to conventional and sporadic MSI-H carcinomas.
    García-Solano J; Conesa-Zamora P; Carbonell P; Trujillo-Santos J; Torres-Moreno D D; Pagán-Gómez I; Rodríguez-Braun E; Pérez-Guillermo M
    Int J Cancer; 2012 Oct; 131(8):1790-9. PubMed ID: 22287190
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heterogeneity of KRAS Mutation Status in Rectal Cancer.
    Jo P; König A; Schirmer M; Kitz J; Conradi LC; Azizian A; Bernhardt M; Wolff HA; Grade M; Ghadimi M; Ströbel P; Schildhaus HU; Gaedcke J
    PLoS One; 2016; 11(4):e0153278. PubMed ID: 27064574
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.